A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease

NCT01958827 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn's Disease

Interventions

BIOLOGICAL: Adalimumab

Sponsor

AbbVie